Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Survodutide
65
CHF
CHF 65.00
In stock
AG-CP3-0046-M0011 mgCHF 65.00
AG-CP3-0046-M0055 mgCHF 230.00
AG-CP3-0046-M02525 mgCHF 690.00
BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.
| Product Details | |
|---|---|
| Synonyms | BI-456906; EX-A7878; GTPL13383 |
| Product Type | Chemical |
| Properties | |
| Formula |
C192H289N47O61 |
| MW | 4231.7 |
| Sequence |
H-His-{Ac4c}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{diacid-C18-gamma-Glu-Gly-Ser-Gly-Ser-Gly-Gly-Lys}-Trp-Leu-Glu-Ser-Ala-NH2 |
| CAS | 2805997-46-8 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White powder. |
| Solubility | Soluble in water (10mg/ml). |
| InChi Key | MEDXQFAHWBMVIM-PCLHIQTFSA-N |
| Smiles | C[C@@H](C(N)=O)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CCCCNC(CNC(CNC([C@H](CO)NC(CNC([C@H](CO)NC(CNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC4=CC=C(O)C=C4)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC6=CC=CC=C6)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC(C7(NC([C@H](CC8=CNC=N8)N)=O)CCC7)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
-
Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R.
-
Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake.
-
Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.
Product References
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy: T. Zimmermann, et al.; Mol. Metab. 66, 101633 (2022)
- 749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers: R. Augustin, et al.; Diabetes 72, 749-P (2023)
- Perspectives in weight control in diabetes - Survodutide: T. Klein, et al.; Diabetes Res. Clin. Pract. 207, 110779 (2024)
Related Products
